Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Rhea-AI Summary

Hansa Biopharma (Nasdaq Stockholm: HNSA) announced its participation in the Truist Securities BioPharma Symposium on November 7 in New York. Chief R&D Officer Hitto Kaufmann will join a panel discussion on 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' from 10:30 to 11:20 AM EST.

The company recently completed a 12-month follow-up analysis of the NICE-01 trial for HNSA-5487, their next-generation molecule. Results show the drug effectively reduces IgG levels rapidly, offers redosing potential, and maintains a favorable safety profile. Hansa, a pioneer in immunological treatments, has developed a first-in-class IgG antibody-cleaving enzyme therapy for kidney transplantation in highly sensitized patients.

LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights:  Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' on Thursday November 7th from 10:30 to 11:20 AM EST.

Recently Hansa conducted a 12-month follow up analysis of data from the NICE-01 trial of HNSA-5487, the company's next generation molecule. The analysis demonstrates that HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile.

Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.

To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here.

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

^©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-attend-truist-securities-biopharma-symposium,c4057639

The following files are available for download:

https://mb.cision.com/Main/1219/4057639/3079341.pdf

20241017_Truist HC Conf_press release_FINAL

 

View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-to-attend-truist-securities-biopharma-symposium-302291270.html

SOURCE Hansa Biopharma AB

FAQ

What are the key findings from Hansa Biopharma's NICE-01 trial for HNSA-5487?

The 12-month follow-up analysis showed that HNSA-5487 can rapidly reduce IgG levels, has redosing potential, and demonstrates a favorable safety and tolerability profile.

When and where is Hansa Biopharma presenting at the Truist Securities BioPharma Symposium?

Hansa Biopharma is presenting on November 7, 2024, from 10:30 to 11:20 AM EST in New York, NY, participating in a panel discussion about inflammatory therapeutics.

What is Hansa Biopharma's (HNSA) main therapeutic breakthrough?

Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy that enables kidney transplantation in highly sensitized patients.